Verinurad: A Comprehensive Guide to URAT1 Inhibition for Gout and Hyperuricemia Management
Discover the science behind Verinurad, a key player in managing uric acid levels and treating gout.
Get a Quote & SampleProduct Core Value
URAT1 Inhibitor
Verinurad is a highly effective inhibitor of the URAT1 transporter, crucial for managing uric acid levels in the body. Its selective action offers a promising therapeutic avenue for conditions like gout and hyperuricemia.
- Explore the Verinurad URAT1 inhibitor mechanism for effective uric acid regulation.
- Learn how Verinurad for gout treatment is progressing in clinical trials.
- Understand the CAS 1352792-74-5 mechanism of action in targeting uric acid reabsorption.
- Investigate the RDEA3170 drug development pipeline and its therapeutic potential.
Key Advantages
Selective URAT1 Inhibition
Verinurad exhibits high affinity and selectivity for the human URAT1 transporter, ensuring targeted action with minimized off-target effects. This precision is key for effective uric acid management.
Therapeutic Potential for Gout
As a potent selective uric acid reabsorption inhibitor, Verinurad shows significant promise in clinical studies for the treatment of gout and hyperuricemia, aiming to reduce elevated serum uric acid levels.
Advanced Pharmaceutical Intermediate
With a purity often exceeding 98%, this compound serves as a critical pharmaceutical intermediate, supporting the development of novel therapies. Understanding hyperuricemia treatment options is vital.
Key Applications
Gout Treatment
Verinurad is being developed as a treatment for gout, a condition characterized by the buildup of uric acid crystals in the joints.
Hyperuricemia Management
Its ability to inhibit URAT1 makes it effective in lowering high levels of uric acid in the blood, a condition known as hyperuricemia.
Pharmaceutical Research
Serves as a vital research chemical for studies investigating URAT1 transporter function and developing new uricosuric agents.
Drug Discovery & Development
A key compound in the pipeline for new drug development targeting metabolic and inflammatory diseases.